GPRC5D recombinant proteins and antibodies

G-protein coupled receptor class C group 5 member D (GPRC5D) is a G-protein coupled receptor (GPCR) that is widely expressed in various cell types, particularly in hematologic malignancies such as multiple myeloma (MM). In recent years, GPRC5D has attracted increasing attention as a potential target for cancer therapy. Research has shown that GPRC5D is highly expressed on tumor cells, particularly in multiple myeloma, while its expression in normal tissues is either absent or minimal, making it an ideal tumor-specific target for therapy.

Although the precise mechanisms of GPRC5D in cancer biology are still under investigation, studies suggest that it may be involved in tumor cell proliferation, metastasis, and immune evasion. This makes GPRC5D a promising target for therapeutic development, particularly in antibody-based therapies. Currently, the ongoing drug development targeting GPRC5D is primarily focused on monoclonal antibodies. For instance, some monoclonal antibodies specifically bind to and block GPRC5D, enhancing the immune system’s ability to recognize and eliminate tumor cells. Additionally, antibody-drug conjugates (ADCs) are being developed to deliver cytotoxic drugs directly to GPRC5D-expressing tumor cells, improving efficacy and minimizing toxicity to normal tissues.

With growing interest in this target, several major pharmaceutical companies have entered the field, aiming to capture a share of the GPRC5D-targeted drug market. Notable companies such as Acri, Johnson & Johnson, and Sanofi have made significant investments in the development of GPRC5D-targeted antibodies and are conducting clinical trials. These companies seek to offer more precise and effective treatment options, particularly for patients with refractory hematologic cancers like multiple myeloma.

To assist in the development of GPRC5D targeted therapies, DIMA BIOTECH can now provide a full range of products and services for GPRC5D targets. Products include active proteins, reference antibodies, and FC-verified monoclonal antibodies; services include customized services for antibodies against multiple genus proteins, antibody humanization, and affinity maturation services. In addition, to accelerate the development of GPRC5D biotherapy, DIMA BIOTECH has also prepared a GPRC5D target single B cell seed library, from which lead antibody molecules can be obtained in as fast as 28 days; at the same time, we have currently screened out multiple GPRC5D IgG sequence ready to out-liscensing, and customers can get the molecules for functional evaluation and verification the next day.